<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2837">
  <stage>Registered</stage>
  <submitdate>8/07/2010</submitdate>
  <approvaldate>8/07/2010</approvaldate>
  <nctid>NCT01159873</nctid>
  <trial_identification>
    <studytitle>Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>C37251/1080</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Bone Loss</healthcondition>
    <healthcondition>Osteoporosis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CEP-37251
Treatment: drugs - Placebo

Experimental: CEP-37251 - 

Placebo Comparator: Placebo - 


Treatment: drugs: CEP-37251
up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) dose of 0.3 mg/kg will be studied.

Treatment: drugs: Placebo
up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Characterize the Overall Safety Assessment of CEP-37251 - Measurements include adverse events, laboratory results, vital sign measurements, electrocardiogram findings, physical examination findings, injection site evaluations, concomitant medication usage, immunophenotyping test results, and immunogenicity test results.</outcome>
      <timepoint>70 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Characterize the Overall Pharmacokinetic Profile of CEP-37251 - Pharmacokinetic parameters include Cmax (Maximum Concentration) and AUC (Area Under the Curve) plasma concentration</outcome>
      <timepoint>70 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Characterize the Overall Pharmacodynamic Effect of CEP-37251 - Pharmacodynamic effect as measured by markers of bone metabolism</outcome>
      <timepoint>70 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  The subject is a postmenopausal woman aged 40 years or greater but less than 75 years.

          -  The subject is ambulatory and healthy as judged by medical examination, medical
             history, and clinical chemistry, hematology and urinalysis at screening.

          -  The subject has a body weight greater than 50 kg but no more than 100 kg with a body
             mass index (BMI) of 18 to 35 kg/m2).

          -  The subject has a normal or clinically acceptable ECG.

          -  The subject is willing to give written informed consent prior to any study-related
             procedures being conducted.

          -  The subject is willing and able to comply with the study restrictions and to remain in
             the study center for the required inpatient period.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>74</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  The subject has received any of the following medications within the 6 months prior to
             enrollment:

               -  hormone replacement therapy

               -  selective estrogen receptor modulator (SERM) therapy such as raloxifene

               -  elemental calcium supplementation &gt;1.5 g/day

               -  Vitamin D supplementation &gt;1000 IU per day

               -  calcitriol or other Vitamin D analogs (eg, alfacalcidol, doxercalciferol, or
                  paricalcitol)

               -  calcitonin or parathyroid hormone

               -  chronic use of glucocorticoids NOTE: Acute use of glucocorticoids may be
                  permitted after consultation with the medical monitor if it occurred a minimum of
                  6 weeks prior to enrollment

               -  anabolic steroids

          -  The subject has received bisphosphonates or fluoride within the 12 months prior to
             enrollment.

          -  The subject has any of the following concomitant conditions:

               -  hypo- or hyperthyroidism. NOTE: Subjects with treated hypothyroidism with normal
                  thyroid parameters may be allowed to participate in the study at the discretion
                  of the investigator and medical monitor.

               -  hypo- or hyperparathyroidism

               -  recent fracture (within 6 months)

               -  osteomalacia, Paget's Disease, osteopetrosis, osteogenesis imperfect, or other
                  bone disease

               -  rheumatoid arthritis or psoriatic arthritis

               -  acute osteoarthritis or gout

               -  chronic kidney disease or renal failure defined as an eGFR (by MDRD equation) 30
                  mL/min/1.73 m2 or less

          -  The subject is receiving immunosuppressant drugs.

          -  The subject is currently participating in another investigational study or has
             received any investigational drug within 60 days before the dose of study drug.

          -  The subject has evidence of severe, progressive, or uncontrolled renal, hepatic,
             hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, psychiatric,
             or cerebral disease, or malabsorption syndrome.

          -  The subject has a known history or evidence of malignancy, lymphoproliferative, or
             neoplastic disease with the exception of being successfully treated for basal or
             squamous cell carcinoma of the skin or cervical intraepithelial neoplasia.

          -  The subject has had any substantial change in levels of physical activity or
             participated in intense physical activity (e.g., marathon training) within the 6
             months prior to the dose of study drug.

          -  The subject has any other clinically significant disease or disorder or factors, such
             as substance abuse, which in the opinion of the investigator, make the subject
             ineligible for participation in this study.

          -  The subject has a known or suspected hypersensitivity or idiosyncratic reaction to any
             compound present in the study drug or placebo.

          -  The subject has habitually consumed, within the past 2 years, more than 21 units of
             alcohol per week, or has a history of alcohol, narcotic, or any other substance abuse
             as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth
             Edition, Text Revision (DSM-IV-TR). NOTE: A unit of alcohol is equal to approximately
             30 ml of spirits, 100 ml of wine, or 260 ml of full-strength beer.

          -  The subject has, within 2 weeks before administration of the dose of study drug, a
             clinically significant excessive consumption of coffee, tea, and/or other
             caffeine-containing beverage or food (i.e., 600 mg of caffeine or more per day, or 5
             or more cups of coffee per day), or a combination of any of these beverages or foods.

          -  The subject has had, within 4 weeks before the dose of study drug, a clinically
             significant illness or, within 1 week before the dose of study drug, has had any acute
             illness, or at screening or on the day before the dose of study drug, has symptoms of
             any clinically significant or acute illness.

          -  The subject has, after resting for 5 minutes, elevated blood pressure (defined as a
             systolic blood pressure of more than 140 mm Hg for subjects =50 years of age or 155 mm
             Hg for subjects &gt;50 years of age and/or a diastolic blood pressure of more than 90 mm
             Hg) or has low blood pressure (defined as systolic blood pressure of less than 90 mm
             Hg and/or diastolic blood pressure of less than 45 mm Hg).

          -  The subject has, after resting for 5 minutes, a pulse less than 45 beats per minute
             (bpm). The subject has, after resting for 5 minutes, a pulse more than 90 bpm for
             subjects =50 years of age or a pulse more than 100 bpm for subjects &gt;50 years of age.

          -  The subject has a positive test result for hepatitis B surface antigen (HBsAg) or
             antibodies to hepatitis C or human immunodeficiency virus (HIV).

          -  History of any clinically important drug and/or vaccine allergies.

          -  The subject has received immunization with a live or live attenuated vaccine within 3
             months prior to the dose of study drug or has immunization with a live or live
             attenuated vaccine planned within 3 months after the dose of study drug.

          -  The subject has an ongoing active systemic infection requiring treatment or a history
             of severe infection, such as hepatitis or pneumonia, in the 3 months prior to the dose
             of study drug. Less severe infections in the 3 months prior to the dose of study drug
             are permitted at the discretion of the investigator and medical monitor.

          -  The subject has a positive alcohol serum, urine, or breath test result or a positive
             urine drug screen (UDS).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>2</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Cephalon Investigational Site - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Cephalon</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in
      Healthy Postmenopausal Women.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01159873</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sr. Director, Clinical Pharmacology and Experimental Medicine, MD</name>
      <address>Cephalon</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>